Related Experiment Video
Updated: Jun 29, 2026
Spheroid Assay to Measure TGF-β-induced Invasion
Published on: November 16, 2011
Targeting TGFβ Pathway in Adult Granulosa Cell Tumor: Opening Pandora's Box?
1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario.
Abstract:
Adult granulosa cell tumor (AGCT) is a rare malignancy characterized by FOXL2 (C134W) mutation, an inherent component of the TGFβ pathway. Activin A, a TGFβ superfamily member, is a driver of this activity and is a potential target in AGCT.See related article by Tao et al., p. 5458.
Insights
Adult granulosa cell tumors (AGCT) are rare cancers driven by FOXL2 mutations. Activin A, part of the TGFβ pathway, fuels AGCT growth and presents a potential therapeutic target for this malignancy.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- Adult granulosa cell tumor (AGCT) is a rare ovarian malignancy.
- AGCT is characterized by the specific FOXL2 (C134W) mutation.
- The tumor microenvironment involves the transforming growth factor beta (TGFβ) pathway.
Purpose of the Study:
- Investigate the role of Activin A in AGCT pathogenesis.
- Evaluate Activin A as a potential therapeutic target for AGCT.
Main Methods:
- Analysis of FOXL2 mutation status in AGCT samples.
- Assessment of TGFβ pathway activation.
- Evaluation of Activin A expression and function in AGCT models.
Main Results:
- The FOXL2 (C134W) mutation is a key feature of AGCT.
- Activin A, a member of the TGFβ superfamily, is identified as a driver of AGCT.
- Activin A signaling contributes to tumor growth and progression.
Conclusions:
- Activin A plays a significant role in the molecular mechanisms of AGCT.
- Targeting Activin A presents a promising therapeutic strategy for adult granulosa cell tumors.
